跳至主要内容
临床试验/NCT03934749
NCT03934749终止不适用

Non-invasive Home Ventilation in Patients With Severe Hypercapnic COPD: Standard Versus Löwenstein Mode of Management of Dynamic Hyperinflation; Effects on Hematosis and Sleep.

Centre Hospitalier Universitaire de Besancon1 个研究点 分布在 1 个国家目标入组 1 人开始时间: 2019年6月27日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
1
试验地点
1
主要终点
Mean carbon dioxide partial pressure-level during non invasive ventilation

研究概览

简要总结

In COPD patients with chronic hypercapnic respiratory failure, the prognosis is poor and the treatment with non invasive ventilation is actually well established. However the best mode of ventilation is not well known.

In severe COPD patients various disorders of respiratory mechanics result in insufficient ventilation, which can be life-threatening or create NIV discomfort. The main characteristic of these disorders is a cyclical closing of small airways that can limit an expiratory flow and provoked some fluctuations in flow curve. To our knowledge, the management of dynamic hyperinflation seems to play an important role in explaining the effect of the NIV. Few studies have examined the effects of the machine's adjustments on dynamic hyperinflation.

The main objective of this study is to analyze the impact of specific ventilatory modes supposed to reduce the dynamic hyperinflation on the hematosis, by studying transcutaneous pressure of carbon dioxide, in severe hypercapnic COPD patients ventilated by NIV. Two modes of ventilation will be compared. First one is an algorithmic mode developed by the company Löwenstein (AirTrap Control, Trigger Lockout and the Expiratory Pressure Ramp). The second one is a standard algorithmic mode, used in the same ventilator. These two ventilatory modes will be evaluated in each patient, during two consecutive nights in current living conditions at home.

研究设计

研究类型
Observational
观察模型
Case Crossover
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Diagnosis of COPD using Gold 2017 criterion
  • Optimal medical treatment of COPD, ie. inhaled steroids, long-acting β2-agonist, long-acting anticholinergic, according to GOLD 2017 guidelines.
  • At least one acute exacerbation of COPD with hypercapnic respiratory failure
  • Introduction of NIV distant to acute exacerbation of COPD with persisting hypercapnia (> 7kPa) on arterial blood gas at rest.
  • NIV equipment from the service provider "Don Du Souffle (DDS)".
  • Patient able to give their consent

排除标准

  • Contraindication to NIV (consensus conference of SFAR-SPLF-SRLF)
  • Obstructive sleep apnea with apnea/hypopnea index > to 20/h
  • BMI > 35 kg/m2
  • Low compliance with NIV treatment (<3h per day)
  • Acute exacerbation COPD during inclusion or pH <7.30 in routine blood gas arterial
  • Severe heart failure (New York Heart Association stage IV/IV)
  • Unstable angina
  • Severe arrhythmias
  • Severe renal insufficiency stage > 4
  • Other conditions than COPD resulting in hypercapnia
  • Pregnancy
  • Patient without health insurance
  • Patient excluded by another study

结局指标

主要结局

Mean carbon dioxide partial pressure-level during non invasive ventilation

时间窗: 2 nights

Mean pCO2 level over night calculated using transcutaneous measurement of partial pressure of carbon dioxide under non invasive ventilation. Device : transcutaneous capnography (PtcCO2); SenTec Digital Monitoring System

次要结局

  • Sleep quality(2 nights)
  • Ventilation quality(2 nights)
  • Number of respiratory events during non invasive ventilation(2 nights)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验